BRPI0513321A - vìrus parapox em combinação com outros agentes antivirais para o tratamento de doenças virais - Google Patents

vìrus parapox em combinação com outros agentes antivirais para o tratamento de doenças virais

Info

Publication number
BRPI0513321A
BRPI0513321A BRPI0513321-1A BRPI0513321A BRPI0513321A BR PI0513321 A BRPI0513321 A BR PI0513321A BR PI0513321 A BRPI0513321 A BR PI0513321A BR PI0513321 A BRPI0513321 A BR PI0513321A
Authority
BR
Brazil
Prior art keywords
combination
treatment
viral diseases
agents
parapox virus
Prior art date
Application number
BRPI0513321-1A
Other languages
English (en)
Inventor
Daniela Paulsen
Helga Ruebsamen-Waigmann
Amar Kureishi
Gerhard Hunsmann
Christiane Stahl-Hennig
Andreas Meyerhans
Alexandra Schuetz
Olaf Weber
Original Assignee
Aicuris Gmbh & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35115792&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0513321(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aicuris Gmbh & Co Kg filed Critical Aicuris Gmbh & Co Kg
Publication of BRPI0513321A publication Critical patent/BRPI0513321A/pt
Publication of BRPI0513321B1 publication Critical patent/BRPI0513321B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24211—Parapoxvirus, e.g. Orf virus
    • C12N2710/24232—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

VìRUS PARAPOX EM COMBINAçãO COM OUTROS AGENTES ANTIVIRAIS PARA O TRATAMENTO DE DOENçAS VIRAIS. A presente invenção refere-se ao uso de vírus Parapox em combinação com outros agentes para o tratamento de doenças virais, e em particular infecções de HIV e AIDS. A invenção também refere-se a processos para produção de medicamentos baseados em combinações de vírus Parapox e outros agentes antivirais. Em particular, a invenção refere-se ao uso de vírus parapox em combinação com agentes do tipo usado para terapia anti-retroviral e terapia anti-retroviral altamente ativa (HAART).
BRPI0513321-1A 2004-07-13 2005-07-08 Vírus parapox em combinação com outros agentes antivirais para o tratamento de doenças virais BRPI0513321B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP04016414 2004-07-13
EP04016414.7 2004-07-13
PCT/EP2005/007395 WO2006005529A1 (en) 2004-07-13 2005-07-08 Parapoxviruses in combination with other antiviral agents for the treatment of hiv/aids

Publications (2)

Publication Number Publication Date
BRPI0513321A true BRPI0513321A (pt) 2008-05-06
BRPI0513321B1 BRPI0513321B1 (pt) 2022-03-08

Family

ID=35115792

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0513321-1A BRPI0513321B1 (pt) 2004-07-13 2005-07-08 Vírus parapox em combinação com outros agentes antivirais para o tratamento de doenças virais

Country Status (14)

Country Link
US (1) US8343478B2 (pt)
EP (1) EP1765370B1 (pt)
JP (1) JP4897677B2 (pt)
CN (2) CN1984666A (pt)
AT (1) ATE442155T1 (pt)
BR (1) BRPI0513321B1 (pt)
CA (1) CA2573204C (pt)
DE (1) DE602005016552D1 (pt)
DK (1) DK1765370T3 (pt)
ES (1) ES2330540T3 (pt)
HK (1) HK1097467A1 (pt)
PL (1) PL1765370T3 (pt)
PT (1) PT1765370E (pt)
WO (1) WO2006005529A1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015520754A (ja) * 2012-05-18 2015-07-23 オタゴ イノベーション リミテッド 創傷治癒のための組合せ治療および組成物
TW201919675A (zh) * 2017-09-07 2019-06-01 德商艾庫瑞斯公司 使用羊副痘疹病毒(Parapoxvirus ovis；PPVO)及至少一種額外抗病毒藥之經B型肝炎病毒(HBV)感染之個體之組合療法
JP2021516957A (ja) 2018-03-07 2021-07-15 トランジェーヌＴｒａｎｓｇｅｎｅ パラポックスウイルスベクター
SI3906970T1 (sl) * 2020-05-08 2022-11-30 Aicuris Gmbh & Co. Kg Parapoksvirus za kondicioniranje in zdravljenje koronavirusnih okužb
WO2023083943A1 (en) * 2021-11-10 2023-05-19 Aicuris Gmbh & Co. Kg Parapoxvirus for preparing for and treatment of respiratory virus infections in combination with antivirals
WO2023083950A1 (en) * 2021-11-10 2023-05-19 Aicuris Gmbh & Co. Kg Parapoxvirus for preparing for and treatment of respiratory virus infections in combination with immunomodulators
WO2024062098A1 (en) 2022-09-23 2024-03-28 Transgene Recombinant pseudocowpox virus encoding an interleukin-12

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4405841C1 (de) * 1994-02-23 1995-01-05 Mayr Anton Prof Dr Med Vet Dr Multipotente Paramunitätsinducer auf der Basis von Kombinationen von Pockenviruskomponenten, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE59712852D1 (de) * 1996-02-28 2007-07-19 Bayer Healthcare Ag Parapockenviren, die fremd-dna enthalten, ihre herstellung und ihre verwendung in impfstoffen
HU224308B1 (hu) * 1996-04-15 2005-07-28 Anton Mayr Attenuált, nem immunogén poxvírusokból vagy parapoxvírusokból származó multipotens parapox immunitás-inducerek alkalmazása gyógyszerkészítmények előállítására
DE19922407A1 (de) * 1999-05-14 2000-11-16 Bayer Ag Organ-, gewebs- und zellspezifisches Immuntherapeutikum für chronische virale Infektionen, sowie entzündliche, degenerative und proliferative Erkrankungen insbesondere der Leber sowie Krebs auf der Basis von rekombinantem Parapoxvirus
EP1303286B1 (de) * 2000-07-11 2006-04-26 Bayer HealthCare AG Verwendung von stämmen des parapoxvirus ovis zur herstellung von antiviralen arzneimitteln und arzneimitteln gegen krebs

Also Published As

Publication number Publication date
CA2573204C (en) 2011-09-20
US20100255032A1 (en) 2010-10-07
CN103800382A (zh) 2014-05-21
CN1984666A (zh) 2007-06-20
PT1765370E (pt) 2009-09-23
JP4897677B2 (ja) 2012-03-14
ATE442155T1 (de) 2009-09-15
WO2006005529A1 (en) 2006-01-19
PL1765370T3 (pl) 2010-02-26
DE602005016552D1 (de) 2009-10-22
BRPI0513321B1 (pt) 2022-03-08
ES2330540T3 (es) 2009-12-11
HK1097467A1 (en) 2007-06-29
DK1765370T3 (da) 2009-11-02
JP2008505952A (ja) 2008-02-28
US8343478B2 (en) 2013-01-01
EP1765370A1 (en) 2007-03-28
EP1765370B1 (en) 2009-09-09
CA2573204A1 (en) 2006-01-19

Similar Documents

Publication Publication Date Title
BRPI0513321A (pt) vìrus parapox em combinação com outros agentes antivirais para o tratamento de doenças virais
BRPI0518984A2 (pt) anÁlogos de nucleosÍdeo de ciclobutil substituÍdos em 2' e 3' para tratamento de infecÇÕes virais e proliferaÇço celular anormal
MX2020006864A (es) Modalidades combinadas para inhibidores de nucleosidos y/o nadph oxidasa (nox) como agentes antivirales especificos de mieloides.
FR16C0028I2 (fr) Vecteurs viraux et utilisation de ces derniers dans des methodes therapeutiques
WO2022217154A3 (en) Modified nucleosides and nucleotides analogs as antiviral agents for corona and other viruses
WO2007033444A3 (en) Antiviral therapy with carbohydrate binding agents
ATE541844T1 (de) Antivirale verbindungen
DE602006015861D1 (de) Antivirale verbindungen
EA200700243A1 (ru) Способы лечения гепатита с
EA200602289A1 (ru) Применение иматиниба для лечения нарушений работы печени и вирусных инфекций
BRPI0411900B8 (pt) compostos e composições farmacêuticas compreendendo os mesmos
CL2011000571A1 (es) Uso de una combinacion de: a) un compuesto de formula (1) o una sal farmaceuticamente aceptable del mismo, b) interferon alfa y c) ribavirina para preparar un medicamento util para el tratamiento de una infeccion viral de la hepatitis c (hcv) o para aliviar uno o mas sintomas de la misma.
SG170825A1 (en) Phosponate nucleosides useful as active ingredients in pharmaceutical compositions for the treatment of viral infections, and intermediates for their production
DE60216151D1 (de) Langwirkende Fusionspeptidinhibitoren gegen HIV-Infektion
TW200510343A (en) Substituted dihydroquinazolines
WO2009094191A3 (en) Methods of treating viral infections
PT1242119E (pt) Combinacoes para o tratamento de infeccoes por virus adn incluindo um diuretico de ansa e um glicosido cardiotonico
WO2006045616A3 (en) β-L-N4-HYDROXYCYTOSINE DEOXYNUCLEOSIDES AND THEIR USE AS PHARMACEUTICAL AGENTS IN THE PROPHYLAXIS OR THERAPY OF VIRAL DISEASES
BR112022016653A2 (pt) Pld para uso em combinação no tratamento de coronavírus
WO2004052905A3 (en) Antiviral nucleoside derivatives
WO2006019841A3 (en) Treatment of viral infections with egr 1 activators
BRPI0406985A (pt) Terapia de combinação de hcv
BR0008269A (pt) Uso de uma preparação de m. vaccae, e, método para tratamento de infecção viral crÈnica, excluindo infecção por hiv
ATE393768T1 (de) Nukleosidanaloga mit antiviraler wirkung
TH95730B (th) การใช้อิมมาทินิบเพื่อรักษาความผิดปรกติของตับและการติดเชื้อไวรัส

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06H Technical and formal requirements: requirement cancelled [chapter 6.8 patent gazette]

Free format text: REF. A RPI NO 2150 DE 20/03/2012. ANULACAO DA EXIGENCIA 6.6 POR TER SIDO INDEVIDA. REQUERENTE NAO APRESENTOU RESPOSTA A EXIGENCIA CONFORME DISPOE A RESOLUCAO 207 DE 24/04/2009, ENTRETANTO, A RESPOSTA CONSTA NO FORMULARIO DE DEPOSITO.

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 08/07/2005, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 19A ANUIDADE.